Home » Stocks » GILD

Gilead Sciences, Inc. (GILD)

Stock Price: $62.75 USD -0.26 (-0.41%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
Pre-market: $62.83 +0.08 (0.13%) Mar 4, 8:03 AM
Market Cap 78.85B
Revenue (ttm) 24.69B
Net Income (ttm) 123.00M
Shares Out 1.26B
EPS (ttm) 0.10
PE Ratio 640.31
Forward PE 8.70
Dividend $2.72
Dividend Yield 4.33%
Trading Day March 3
Last Price $62.75
Previous Close $63.01
Change ($) -0.26
Change (%) -0.41%
Day's Open 62.80
Day's Range 62.17 - 63.32
Day's Volume 5,906,080
52-Week Range 56.40 - 83.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company's HIV, hepatitis C virus (HCV), and COVID-19 r...

Investors Business Daily - 6 days ago

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: AZN, BNTX, GSK, ILMN, JNJ, LLY, MRNA, NVAX, PACB, PFE, REGN, TMO, VIR
Zacks Investment Research - 6 days ago

FATE reports a wider Q4 loss on increased R&D expenses.

Other stocks mentioned: BMY, FATE, JNJ
The Motley Fool - 1 week ago

Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.

Other stocks mentioned: AMZN, BMY, INFI, NVAX, RHHBY, SHOP, TRIL, WMT
Business Wire - 2 weeks ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Health...

Zacks Investment Research - 2 weeks ago

Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.

Other stocks mentioned: GLPG
Business Wire - 3 weeks ago

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a new analysis of the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult p...

The Motley Fool - 3 weeks ago

Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.

Other stocks mentioned: GLPG
Benzinga - 3 weeks ago

Galapagos NV (NASDAQ: GLPG) and Gilead Sciences Inc (NASDAQ: GILD) have decided to stop the ISABELA Phase 3 studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF)...

Other stocks mentioned: GLPG
Business Wire - 3 weeks ago

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 cli...

Other stocks mentioned: GLPG
The Motley Fool - 3 weeks ago

These biotechs are developing innovative therapies while doing their part to combat the coronavirus.

Other stocks mentioned: JNJ, REGN
The Motley Fool - 3 weeks ago

The unusual biotech could be a bitter pill for short sellers to swallow.

Other stocks mentioned: GME, JAZZ, JNJ, LGND, MRK, NVS, PFE
Business Wire - 3 weeks ago

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Cl...

Proactive Investors - 3 weeks ago

Gilead Sciences Inc (NASDAQ:GILD) earnings beat forecasts as sales of its antiviral drug remdesivir were boosted by its use as a treatment for coronavirus (COVID-19). Remdesivir is now treatin...

Zacks Investment Research - 3 weeks ago

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Other stocks mentioned: ALXN, AMGN, BBH, BIIB, IBB, XBI
The Motley Fool - 3 weeks ago

Investors liked the big biotech's Q4 update.

Zacks Investment Research - 3 weeks ago

Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.

Benzinga - 3 weeks ago

Gilead Sciences Inc (NASDAQ: GILD) reported revenue in the fourth quarter of $7.3 billion, reflecting a 26% increase from the prior-year period revenue total of $5.8 billion, in-line with the ...

The Motley Fool - 3 weeks ago

Without one drug, Gilead's Q4 update wouldn't have been a good one.

Invezz - 3 weeks ago

Gilead Sciences Inc. (NASDAQ: GILD) said on Thursday that its COVID-19 drug, Veklury, generated £1.39 billion of sales in the fiscal fourth quarter, making up 25% of the company's total quarte...

Zacks Investment Research - 3 weeks ago

Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 weeks ago

Shares of Gilead Sciences (NASDAQ:GILD) rose after the company reported Q4 results. Quarterly Results Earnings per share were up 68.46% year over year to $2.19, which beat the estimate of $2.15.

Reuters - 3 weeks ago

Gilead Sciences Inc posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.

Business Wire - 3 weeks ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 4.4% in the company's quarterly cas...

Business Wire - 3 weeks ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020. “Gilead continues to play a cent...

Business Wire - 1 month ago

FOSTER CITY, Calif. & WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Human Rights Campaign (HRC), the nation's largest lesbian, gay, bisexual, transgender and queer ...

InvestorPlace - 1 month ago

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compell...

Other stocks mentioned: ABBV, AZN, VTRS, BMY, MRK, PFE
Benzinga - 1 month ago

Gilead Sciences, Inc. (NASDAQ: GILD) said Monday that it has entered into a collaboration, option and license agreement with Gritstone Oncology Inc (NASDAQ: GRTS) to develop a vaccine-based im...

Market Watch - 1 month ago

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. A...

Other stocks mentioned: RCUS
Market Watch - 1 month ago

Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to use Gritstone's vaccine platform technology to deve...

Business Wire - 1 month ago

FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing n...

Other stocks mentioned: GRTS
24/7 Wall Street - 1 month ago

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Other stocks mentioned: AMGN, BIIB, MRK, PFE, ABBV, ALXN, BMY, REGN
The Motley Fool - 1 month ago

Great dividends need to be sustainable, and that requires free cash flow.

Other stocks mentioned: O, XOM
Zacks Investment Research - 1 month ago

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.

Zacks Investment Research - 1 month ago

In the latest trading session, Gilead Sciences (GILD) closed at $64.68, marking a -1.22% move from the previous day.

Zacks Investment Research - 1 month ago

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Other stocks mentioned: LLY, MRK, SNY, VRTX
The Motley Fool - 1 month ago

It's been a rocky past few months for the biotech, but is now a good time for investors to pull the trigger?

The Motley Fool - 1 month ago

These are the recently approved treatments biotech investors want to keep their eyes on in 2021.

Other stocks mentioned: GSK, LLY
The Motley Fool - 1 month ago

One has a top COVID-19 treatment, the other has a top COVID-19 vaccine. Which stock will come out on top.

Other stocks mentioned: PFE
Invezz - 1 month ago

Gilead Sciences (NASDAQ: GILD) shares are advancing this January, and at the current stock price, this company is fairly valued, in my opinion. The company is moving in the right direction, an...

Other stocks mentioned: MS
Seeking Alpha - 1 month ago

Gilead has underperformed the S&P 500 in recent years, but that may be set to change as the company returns to growth with market valuations stretched. Gilead not only provides investors with ...

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4...

Zacks Investment Research - 1 month ago

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

The Motley Fool - 1 month ago

Both stocks provide payouts that put the average stock on the S&P 500 to shame.

Other stocks mentioned: TD
The Motley Fool - 1 month ago

A Wall Street analyst upgraded the biotech stock.

Benzinga - 1 month ago

Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew ...

Other stocks mentioned: GLPG
Business Wire - 1 month ago

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Ce...

Seeking Alpha - 1 month ago

Merck and Amgen are major pharmaceuticals that experienced slowing sales in the mid 2010s due to patent expirations and biosimilar competition. However, Merck recently experienced strong botto...

Other stocks mentioned: AMGN, LLY, MRK
Zacks Investment Research - 1 month ago

Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.

About GILD

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Jan 22, 1992
CEO
Daniel O'Day
Employees
13,600
Stock Exchange
NASDAQ
Ticker Symbol
GILD
Full Company Profile

Financial Performance

In 2020, GILD's revenue was $24.69 billion, an increase of 9.98% compared to the previous year's $22.45 billion. Earnings were $123.00 million, a decrease of -97.72%.

Financial Statements

Analyst Forecasts

According to 32 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 74.54, which is an increase of 18.79% from the latest price.

Price Target
$74.54
(18.79% upside)
Analyst Consensus: Buy